EUVIMEDOpdag EUVIMED
Open access

Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors

Mei Feng iD, Hong Liu, Lu Zheng, Yang Liu iD, Hao Zhuang iD, Hao Xu, Tingting Zhang, Zhen Wu, Xiaolong Qian, Huikai Li iD, Tengfei Xiao, Yisheng Pan iD and 2 more

Science Advances · 2026

DOI: 10.1126/sciadv.aeb4348 ↗

At a glance

Journal article in Science Advances, 2026. Written by Mei Feng and 13 co-authors. Institution: International Cancer Institute and Translational Cancer Research Center, Peking University First Hospital, Beijing, China. Major MEDLINE topics: Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Cited 4 times so far (Crossref); 68 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, National Science and Technology Major Project, National Key Research and Development Program of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The nongenetic mechanisms by which cancer cells escape cell cycle inhibition remain inadequately understood. Here, we uncover an epigenetic pathway driving adaptive resistance to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in hepatobiliary cancers using integrative approach combining genome-wide CRISPR screenings with transcriptional, epigenetic, and proteomic profiling. Sustained CDK4/6 inhibition triggers BAP1-dependent chromatin remodeling that induces a stem cell–like epigenetic state. Specifically, BAP1 removes ubiquitin modification (H2AK119ub) at the TCF4 promoter, activating WNT and EMT signaling to enhance cellular plasticity and survival under therapy. Notably, genetic and pharmacologic inhibition of BAP1 markedly improves abemaciclib efficacy in multiple mouse models and patient-derived organoids (PDOs). These findings establish BAP1 as a key regulator of tumor plasticity and adaptive resistance through epigenetic reprogramming and suggest a promising strategy for overcoming adaptive therapeutic CDK4/6i resistance by targeting quiescent, drug-resistant cancer cells.

Subjects

MeSH terms (MEDLINE)

Tumor Suppressor ProteinsUbiquitin ThiolesteraseCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Genome-Wide Association StudyGene Expression Regulation, NeoplasticHumansEpigenesis, GeneticCell Line, TumorDrug Resistance, NeoplasmProtein Kinase InhibitorsLiver NeoplasmsCarcinoma, Hepatocellular

Substances

BAP1 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseCDK4 protein, humanCyclin-Dependent Kinase 4CDK6 protein, humanCyclin-Dependent Kinase 6Protein Kinase Inhibitors

Authors and institutions

  • International Cancer Institute and Translational Cancer Research Center, Peking University First Hospital, Beijing, China.
  • The Second Surgical Department of Breast Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin…
  • Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
  • Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's C…
  • Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin, China.

ORCID profiles: Mei Feng, Yang Liu, Hao Zhuang, Huikai Li, Yisheng Pan, Shaokun Shu, Ning Zhang

Funding

  • National Natural Science Foundation of China
  • National Science and Technology Major Project
  • National Key Research and Development Program of China
  • Postdoctoral Innovation Talent Support Program
  • Fundamental Research Funds for the Central Universities-Peking University Medicine Sailing Program for Young Scholars’ Scientific & Technological Innovation
  • Beijing Natural Science Foundation
  • Baidu Foundation of China

Cite

APA

Feng, M., Liu, H., Zheng, L., Liu, Y., Zhuang, H., Xu, H., Zhang, T., Wu, Z., Qian, X., Li, H., Xiao, T., Pan, Y., Shu, S., & Zhang, N. (2026). Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors. Science Advances. https://doi.org/10.1126/sciadv.aeb4348

Vancouver

Feng M, Liu H, Zheng L, Liu Y, Zhuang H, Xu H, et al. Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors. Science Advances. 2026. doi:10.1126/sciadv.aeb4348

BibTeX
@article{Feng2026,
  author = {Feng, Mei and Liu, Hong and Zheng, Lu and Liu, Yang and Zhuang, Hao and Xu, Hao and Zhang, Tingting and Wu, Zhen and Qian, Xiaolong and Li, Huikai and Xiao, Tengfei and Pan, Yisheng and Shu, Shaokun and Zhang, Ning},
  title = {Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aeb4348}
}
Start for free →